Edgewise Therapeutics Stock (NASDAQ:EWTX)
Previous Close
$11.42
52W Range
$10.60 - $38.12
50D Avg
$23.31
200D Avg
$25.26
Market Cap
$1.30B
Avg Vol (3M)
$1.74M
Beta
0.33
Div Yield
-
EWTX Company Profile
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
EWTX Performance
Peer Comparison
| Ticker | Company |
|---|---|
| MLYS | Mineralys Therapeutics, Inc. |
| RVMD | Revolution Medicines, Inc. |
| CCCC | C4 Therapeutics, Inc. |
| IPSC | Century Therapeutics, Inc. |
| BDTX | Black Diamond Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| PASG | Passage Bio, Inc. |
| CELC | Celcuity Inc. |
| XLO | Xilio Therapeutics, Inc. |
| CGEM | Cullinan Oncology, Inc. |
| VOR | Vor Biopharma Inc. |
| IKNA | Ikena Oncology, Inc. |
| ACET | Adicet Bio, Inc. |